Cytokinetics, Incorporated
CYTK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,267 | $8,059 | $4,116 | $3,504 |
| - Cash | $95 | $113 | $66 | $113 |
| + Debt | $789 | $756 | $749 | $270 |
| Enterprise Value | $5,961 | $8,702 | $4,800 | $3,662 |
| Revenue | $18 | $8 | $95 | $70 |
| % Growth | 145.3% | -92% | 34.3% | – |
| Gross Profit | -$321 | -$323 | -$146 | -$90 |
| % Margin | -1,737.2% | -4,284.1% | -154.6% | -127.1% |
| EBITDA | -$493 | -$457 | -$329 | -$176 |
| % Margin | -2,671.2% | -6,064.9% | -348.2% | -250.4% |
| Net Income | -$590 | -$526 | -$389 | -$215 |
| % Margin | -3,191.1% | -6,988.6% | -411.2% | -305.7% |
| EPS Diluted | -5.26 | -5.45 | -4.33 | -2.8 |
| % Growth | 3.5% | -25.9% | -54.6% | – |
| Operating Cash Flow | -$396 | -$414 | -$300 | -$143 |
| Capital Expenditures | -$4 | -$1 | -$11 | -$49 |
| Free Cash Flow | -$400 | -$416 | -$311 | -$191 |